Trial Profile

A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Revumenib (Primary) ; Venetoclax (Primary) ; Cytarabine; Methotrexate
Indications Acute myeloid leukaemia
Focus Adverse reactions
Acronyms BEAT-AML

Most Recent Events

04 May 2026 Planned primary completion date changed from 1 Jul 2026 to 1 Oct 2026.
30 Apr 2026 According to a Syndax Pharmaceuticals media release, frontline data from the BEAT AML trial of revumenib in combination with venetoclax/azacitidine in NPM1m and KMT2Ar AML expected in the second half of 2026.
03 Nov 2025 Planned End Date changed from 1 Jul 2026 to 1 Apr 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com